respiratory
Cystic fibrosis

Evidence for CFTR combination therapy in advanced CF


Lumacaftor/ivacaftor combination therapy benefits patients with cystic fibrosis homozygous for the Phe508del CFTR mutation with moderate to severe lung dysfunction, a pooled analysis of data from the TRAFFIC and TRANSPORT studies shows. The research team including Dr Stuart Elborn from Queens University in Belfast and Professor Claire Wainwright from the University of Queensland in Australia ...

Already a member?

Enter your email to keep reading.


OR